(5)In addition, the Annex to Commission Implementing Regulation (EU) 2018/1882note, as recently amended by Commission Implementing Regulation (EU) 2026/169note, re-categories infection with bluetongue virus (serotypes 1-24) as a category D+E disease, when it had previously been categorised as a category C+D+E disease. That amendment to Implementing Regulation (EU) 2018/1882 applies from 1 November 2026. As a consequence of such re-categorisation, the rules for infection with bluetongue virus (serotypes 1-24) relating to official disease-free status or to eradication programmes, including the requirements for movements of germinal products when entering into a disease-free Member State or zone thereof or into a Member State or zone thereof subjected to an eradication programme laid down in Part II, Chapter 2, Section 4, of Commission Delegated Regulation (EU) 2020/689note and in Annex V, Part II, thereto, were amended by Commission Delegated Regulation (EU) 2026/797note. Those amendments to Delegated Regulation (EU) 2020/689 apply from 1 November 2026. Therefore, the requirements laid down in those provisions of Delegated Regulation (EU) 2020/689 related to the official disease-free status of a Member State or zone thereof or to carrying out an eradication programme for infection with bluetongue virus (serotypes 1-24) cease to apply from 1 November 2026. Accordingly, Annex II, Part 5, Chapter II, to Delegated Regulation (EU) 2020/686 should be amended by deleting the references to a disease-free status and to an eradication programme for that disease.
Source: EUR-Lex, © European Union, 1998-2026. Reuse authorised under Decision 2011/833/EU.